Whalesbook
Financial Performance
Sanofi India reported a 14% decline in first-quarter net profit, falling to ₹102.6 crore from ₹119.5 crore a year earlier. Revenue decreased by 4.9%, to ₹472.3 crore from ₹535.9 crore in the same period.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) were down 16.9% to ₹142.8 crore, and the EBITDA margin narrowed to 30.2% from 32.1% a year ago. The company attributed these results to transactions linked to partner transitions, which provided a stable base in cardiovascular, oral anti-diabetes, and central nervous system segments but affected overall revenue.
Portfolio Strengths and Outlook
Despite these financial pressures, Sanofi India's domestic insulin portfolio achieved strong double-digit growth for the second consecutive quarter, reinforcing its leading position in the diabetes injectable market. Managing Director Deepak Arora highlighted insulin's ongoing importance in comprehensive diabetes care, noting the segment's consistent year-on-year growth.
Arora expressed confidence that strategic partnerships will drive future growth, expanding the company's commercial footprint and market penetration. Sanofi India is also focusing on efficiency gains through targeted market initiatives and refined strategies. Export sales are beginning to stabilize despite ongoing geopolitical conditions.